Study of Gemcitabine+Platinum Salt+Bevacizumab Combination for Metastatic Collecting Duct Carcinoma (GETUG-AFU 24)
Status:
Completed
Trial end date:
2020-08-01
Target enrollment:
Participant gender:
Summary
Open-label, non-randomized, multicenter, phase II, single arm non comparative trial
evaluating toxicity and efficacy of gemcitabine plus platinum salt in combination with
bevacizumab in first-line setting in metastatic collecting duct carcinoma.